Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||HS-110 + Nivolumab||Phase Ib/II||Actionable||In a Phase I/II trial, HS-110 (Viagenpumatucel-L) and Opdivo (nivolumab) combination treatment demonstrated safety, and resulted in an objective response rate of 21% (10/47), a clinical benefit rate of 43%, a median duration of response of 17.2 months, and a median overall survival of 28.7 months in patients with advanced non-small cell lung cancer (J Clin Oncol 38: 2020 (suppl; abstr 9546); NCT02439450).||detail...|
|PubMed Id||Reference Title||Details|
|Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab.||Full reference...|